For the quarter ending 2025-09-30, MYGN had $71,100K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,400 | -330,600 |
| Depreciation and amortization | 12,600 | 28,500 |
| Non-cash lease expense | 1,000 | 5,600 |
| Stock-based compensation expense | 12,200 | 20,200 |
| Deferred income taxes | 0 | 0 |
| Unrecognized tax benefits | 0 | -31,500 |
| Impairment of goodwill and long-lived assets | 0 | 316,700 |
| Gain on termination of lease | 0 | 0 |
| Gain on acquisition | 0 | 0 |
| Other non-cash adjustments | 1,300 | 300 |
| Prepaid expenses and other current assets | 3,400 | -300 |
| Trade accounts receivable | -19,000 | 15,400 |
| Inventory | 2,900 | 1,200 |
| Prepaid taxes | -500 | -2,100 |
| Other assets | -600 | -700 |
| Accounts payable | -800 | 3,600 |
| Accrued liabilities | 8,400 | -29,200 |
| Net cash used in operating activities | 21,100 | -29,900 |
| Capital expenditures | 2,800 | 8,100 |
| Capitalization of intangible assets | 3,400 | 7,100 |
| Proceeds from the sale of businesses, net of cash sold | 0 | - |
| Proceeds from maturities and sales of marketable investment securities | 0 | 0 |
| Net cash used in investing activities | -6,200 | -15,200 |
| Proceeds from common stock issued under stock-based compensation plans | 0 | 2,700 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | 300 | 5,800 |
| Proceeds from revolving credit facility | 0 | 40,000 |
| Repayment of revolving credit facility | 60,000 | 20,500 |
| Proceeds from the issuance of secured long-term credit facility | 125,000 | - |
| Fees associated with the issuance of secured long-term credit facility | 8,400 | - |
| Payment on finance leases | 100 | 200 |
| Net cash provided by (used in) financing activities | 56,200 | 16,200 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 0 | 700 |
| Change in cash and cash equivalents classified as held for sale | - | 0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 71,100 | -28,200 |
| Cash and cash equivalents at beginning of period | 111,900 | - |
| Cash and cash equivalents at end of period | 154,800 | - |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)